False-Positive Uptake in Splenic Hemangioma on 68Ga-DOTATATE PET/CT

Zhu, B. X.; Yoon, Emily; Mahajan, Sonia; Kranz, Anca-Oana

doi:10.1097/rlu.0000000000004626

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Image interpretation criteria were in line with the European Association of Nuclear Medicine guidelines 8 . A lesion was considered positive if it exhibited radiotracer uptake above liver uptake (Krenning score of 3 or 4) and could not be explained by a benign abnormality (such as splenic hemangioma 9 ). Lesions in locations common for other primary neoplasm, which may show SSTR-2 overexpression (such as focal radiotracer uptake in the thyroid gland), were considered equivocal 10 .…”

Section: Methodsmentioning

confidence: 99%

68Ga-DOTATATE PET/CT in the Initial Diagnosis of Patients With Clinical, Imaging, and/or Biochemical Suspicion of a Neuroendocrine Tumor

Metser,

Ezzat,

Singh

et al. 2023

Clin Nucl Med

View full text Add to dashboard Cite

Purpose The aim of this study was to assess the yield of somatostatin receptor PET in patients with clinical, imaging, and/or biochemical suspicion of a neuroendocrine tumor (NET). Patients and Methods This analysis includes patients referred for the initial diagnosis of an unconfirmed NET, as part of a prospective, single-arm registry study (NCT03873870) assessing the utility of 68Ga-DOTATATE PET/CT in the management of NETs. Inclusion criteria to this cohort consisted of elevated biomarkers and/or clinical presentation suspicious for a NET, with negative conventional cross-sectional imaging, or presence of a lesion suspicious for a NET on conventional imaging, not amenable for biopsy. Patients with histological confirmation of a NET were excluded. Results There were 220 patients included between April 2019 and March 2022 with a mean age ± SD of 59.5 ± 16.1 years with biochemical, morphological, and/or clinical suspicion of a NET. Overall, 132/220 patients (60%) had a positive 68Ga-DOTATATE PET/CT. 68Ga-DOTATATE PET/CT confirmed a type 2 somatostatin receptor overexpressing tumor in 123/171 (71.9%) of patients with a radiographically suspicious abnormality. The positivity rate for pancreatic, small bowel/mesenteric, adrenal, and other sites was 78/96 (81.2%), 38/57 (66.7%), 7/7 (100%), and 1/11 (9.1%), respectively. 68Ga-DOTATATE PET/CT was positive in 9/49 (18.4%) of those with a biochemical and/or clinical suspicion of a NET. Conclusions 68Ga-DOTATATE PET/CT is positive in nearly 3 of 4 patients with morphological suspicion of a NET, with the highest yield in those with pancreatic and small bowel or mesenteric masses, and in approximately 1 of 6 patients with biochemical and/or clinical suspicion of a NET.

show abstract

Section: Methodsmentioning

confidence: 99%